Search Results

Avenue Therapeutics, Inc. today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell’s Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.

Neurelis, Inc., today announced that the company will present six poster presentations at the American Epilepsy Society (AES) Annual Meeting held in Orlando, Florida from December 1 – 5, 2023.

IAMA Therapeutics today announced that it will present a poster titled “Selective NKCC1 Inhibitors for the Treatment of Refractory Epilepsy” at the American Epilepsy Society (AES) 2023 Annual Meeting.

GeneDx today announced new data to be presented at the American Epilepsy Society (AES) annual meeting in Orlando, Florida, December 1-5, 2023, that supports the use of exome sequencing as a first-tier test for patients with epilepsy.

Ovid Therapeutics Inc. today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida.

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society.

NeuroPace, Inc. today announced that the Company will have a substantial presence at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orlando, Florida and virtually from December 1-5, 2023.

The American Cancer Society and the American Society of Clinical Oncology announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online.

UCB announced data being presented at the American Epilepsy Society Annual Meeting, taking place December 1–5 in Orlando, Florida, that focus on the real-world experiences of people living with rare epilepsy syndromes and their caregivers, in addition to several other presentations of clinical data evaluating the efficacy, safety and tolerability of FINTEPLA as a treatment for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome.